To the editor:
I am writing in response to the June 25, 2018, commentary regarding the evolution of care models for diabetic macular edema. I think the conclusions reached in the paper do not accurately reflect physician experience with Iluvien implants in the United States. When addressing the place of steroids in DME, Dr. Lindstrom states: “The double-edged sword of steroids is especially seen ... with Iluvien implants, in which steroid-induced glaucoma is a common occurrence.”
Alimera has two clinical studies capturing real-world Iluvien data. These are the prospective PALADIN
Uncategorized